
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under §240.14a-12

Crinetics Pharmaceuticals, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

No fee required

Fee paid previously with preliminary materials

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



P.O. BOX 8016, CARY, NC 27512-9903

Crinetics Pharmaceuticals, Inc. Important Notice Regarding the Availability of Proxy Materials

**Stockholders Meeting to be held on
June 16, 2023**

For Stockholders of record as of April 17, 2023

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials, and to obtain directions to attend the meeting virtually, go to: www.proxydocs.com/CRNX

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.



**For a convenient way to view proxy materials and VOTE go to
www.proxydocs.com/CRNX**

**Have the 12 digit control number located in the shaded box above available
when you access the website and follow the instructions.**

If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before June 6, 2023.

To order paper materials, use one of the following methods.


INTERNET
www.investorelections.com/CRNX


TELEPHONE
(866) 648-8133


*** E-MAIL**
paper@investorelections.com

When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.

* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

Crinetics Pharmaceuticals, Inc.

Meeting Type: Annual Meeting of Stockholders
Date: Friday, June 16, 2023
Time: 8:00 AM, Pacific Time
Place: Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/CRNX for more details.

You must register to attend the meeting online and/or participate at www.proxydocs.com/CRNX

SEE REVERSE FOR FULL AGENDA

Crinetics Pharmaceuticals, Inc.

Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

FOR ALL THE DIRECTORS ON PROPOSAL 1, FOR ON PROPOSALS 2 AND 3, AND 1-YEAR ON PROPOSAL 4

PROPOSAL

1. To elect three directors to serve as Class II directors for a three-year term to expire at the 2026 annual meeting of stockholders.
 - 1.01 Caren Deardorf
 - 1.02 Weston Nichols, Ph.D.
 - 1.03 Stephanie S. Okey, M.S.
2. To consider and vote upon the ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 31, 2023.
3. To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers.
4. To consider and vote upon, on an advisory basis, whether the stockholder vote to approve the compensation of the Company's named executive officers should occur every one, two or three years.
5. To transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.

